Some experience with 57Co labeled bleomycin as a tumor seeking agent

J.J. Rasker, M.A.P.C. van de Poll, H. Beekhuis, M.G. Woldring, H.O. Nieweg

Research output: Contribution to journalArticleAcademicpeer-review

36 Citations (Scopus)
11 Downloads (Pure)

Abstract

Bleomycin labeled with 57Co was used as a tumor localizing agent in 132 patients. In patients with pulmonary tumors the primary localization concentrated radioactivity in 52 of the 54 appropriate cases; out of the 22 clinically known metastases, 19 were visible on the scan; 40 unknown metastases especially in hilus and mediastinum were found by this method and subsequently confirmed. In 22 patients with malignant lymphomas, 18 out of 22 known pathologic lymph glands above the diaphragm were visible on the scan; below the diaphragm the results of scanning in lymph glands and spleen were disappointing, probably because of the disturbing concentration of radioactivity in the kidneys, the bladder, the liver, and sometimes the gut. In 25 patients with various other tumors, 16 out of 22 known localizations above the diaphragm were visible; 2 were uncertain and 4 negative. Below the diaphragm the results were usually negative. In 24 patients with benign lesions, uptake of 57Co bleomycin was visible on the scintigram in 4 patients with cavitating pulmonary tuberculosis, in 2 with pulmonary infections, in 1 with Caplan lesions of rheumatoid arthritis in the lung, and in 1 with sinusitis ethmoidalis. The significance of these results is discussed.

Original languageEnglish
Pages (from-to)1058-1069
Number of pages12
JournalJournal of nuclear medicine
Volume16
Issue number11
Publication statusPublished - 1 Jan 1975
Externally publishedYes

Fingerprint Dive into the research topics of 'Some experience with <sup>57</sup>Co labeled bleomycin as a tumor seeking agent'. Together they form a unique fingerprint.

  • Cite this

    Rasker, J. J., van de Poll, M. A. P. C., Beekhuis, H., Woldring, M. G., & Nieweg, H. O. (1975). Some experience with 57Co labeled bleomycin as a tumor seeking agent. Journal of nuclear medicine, 16(11), 1058-1069.